Abbott
164 articles with Abbott
-
U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems
3/6/2023
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.
-
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
1/26/2023
Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
-
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
1/25/2023
Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022.
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings - January 4, 2023
1/4/2023
Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.
-
Abbott to Present at J.P. Morgan Healthcare Conference-December 20, 2022
12/20/2022
Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023.
-
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance
10/19/2022
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2022.
-
Abbott Hosts Conference Call for Third-Quarter 2022 Earnings
9/28/2022
Abbott will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens.
-
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
7/20/2022
Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022.
-
Abbott Hosts Conference Call for Second-Quarter Earnings - June 29, 2022
6/29/2022
Abbott will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022, before the market opens.
-
Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
6/5/2022
Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference of 7.9%,1 making it the first and only 14-day continuous glucose monitoring system to achieve a sub-8% overall MARD.
-
Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
5/16/2022
Abbott has agreed to enter into a consent decree with the U.S. Food and Drug Administration related to its Sturgis, Mich., infant formula plant.
-
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
5/4/2022
Abbott announced it has received FDA clearance for its Alinity™ m STI Assay.
-
Abbott Reports First-Quarter 2022 Results
4/20/2022
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2022.
-
Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
4/4/2022
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.
-
Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
2/21/2022
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company's CardioMEMS™ HF System to support the care of more people living with heart failure.
-
Abbott Declares 393rd Consecutive Quarterly Dividend
2/18/2022
The board of directors of Abbott declared a quarterly common dividend of 47 cents per share.
-
Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
2/7/2022
Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart.
-
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
1/26/2022
Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022.
-
Abbott Hosts Conference Call for Fourth-Quarter 2021 Earnings
1/4/2022
Abbott will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.
-
Abbott to Present at J.P. Morgan Healthcare Conference - Dec 21, 2021
12/21/2021
Abbott will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11, 2022. Robert B. Ford, chairman and chief executive officer, will present at 8 a.m. Central time.